Richard H.  Anderson net worth and biography

Richard Anderson Biography and Net Worth

Director of Medtronic
Mr. Anderson served without compensation as the President and Chief Executive Officer of Amtrak, an intercity passenger rail service provider, from July 2017 until his retirement on April 15, 2020. From 2007 until May 2016, Mr. Anderson served as Chief Executive Officer and a director of Delta Air Lines, Inc., a commercial airline. Upon retiring as Chief Executive Officer of Delta Air Lines, Inc. in May 2016, he became the Executive Chairman of the board of directors of Delta Air Lines, Inc. until October 2016. He was Executive Vice President of UnitedHealth Group Incorporated, a diversified health care company, from 2004 until 2007. Mr. Anderson was Chief Executive Officer of Northwest Airlines Corporation from 2001 to 2004. Mr. Anderson is a former director of Delta Air Lines, Inc.

What is Richard H. Anderson's net worth?

The estimated net worth of Richard H. Anderson is at least $265,380.00 as of July 29th, 2024. Mr. Anderson owns 3,000 shares of Medtronic stock worth more than $265,380 as of November 18th. This net worth evaluation does not reflect any other investments that Mr. Anderson may own. Learn More about Richard H. Anderson's net worth.

How do I contact Richard H. Anderson?

The corporate mailing address for Mr. Anderson and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Richard H. Anderson's contact information.

Has Richard H. Anderson been buying or selling shares of Medtronic?

Richard H. Anderson has not been actively trading shares of Medtronic over the course of the past ninety days. Most recently, on Thursday, December 16th, Richard H. Anderson bought 5,010 shares of Medtronic stock. The stock was acquired at an average cost of $103.26 per share, with a total value of $517,332.60. Learn More on Richard H. Anderson's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 4 times. They sold a total of 55,659 shares worth more than $4,695,766.41. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Richard H. Anderson Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2021Buy5,010$103.26$517,332.60View SEC Filing Icon  
10/8/2020Buy4,607$108.52$499,951.64View SEC Filing Icon  
12/6/2019Buy5,000$111.13$555,650.00View SEC Filing Icon  
5/24/2019Buy10,900$92.40$1,007,160.0089,912View SEC Filing Icon  
8/23/2018Buy2,600$95.88$249,288.00View SEC Filing Icon  
6/21/2017Buy5,600$88.90$497,840.0071,910View SEC Filing Icon  
5/22/2013Buy4,800$52.32$251,136.00View SEC Filing Icon  
See Full Table

Richard H. Anderson Buying and Selling Activity at Medtronic

This chart shows Richard H Anderson's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $87.64
Low: $87.04
High: $88.72

50 Day Range

MA: $89.48
Low: $85.97
High: $92.27

2 Week Range

Now: $87.64
Low: $74.66
High: $92.68

Volume

10,339,780 shs

Average Volume

6,243,852 shs

Market Capitalization

$112.39 billion

P/E Ratio

29.61

Dividend Yield

3.20%

Beta

0.84